Longer-term therapeutic responses with significantly improved efficacy over chemotherapy can be achieved with mTOR inhibitors in malignant PEcoma, especially in patients with mutations in the TSC1/TSC2 genes that result in aberrant activation of the mTOR pathway. Here, MTOR is linked to neoplasm with perivascular epithelioid cell differentiation.